Pharmacokinetic Comparison of Orally Disintegrating and Conventional Donepezil Formulations in Healthy Korean Male Subjects: A Single-Dose, Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 965-972

  Kim, Kyoung Ah ^a   Lim, Jong Lae ^b   Kim, Chin ^b   Park, Ji Young ^a  

^a Korea University College of Medicine   (South Korea)

^b Chong Kun Dang Research Institute   (South Korea)

Author keywords

Donepezil pharmacokinetic; Equivalence pharmacokinetics

Indexed keywords

DONEPEZIL;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TABLET DISINTEGRATION; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; REPUBLIC OF KOREA; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 79960236644     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.003     Document Type: Article

References (29)

1. Ogura H., Kosasa T., Kuriya Y., Yamanishi Y. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur J Pharmacol 2001, 415:157-164.
2. Sugimoto H., Ogura H., Arai Y., et al. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002, 89:7-20.
3. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998, 158:1021-1031.
4. Birks J., Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006, ACD001190.
5. Doody R.S. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999, 45(Suppl 1):23-32.
6. Feldman H., Gauthier S., Hecker J., et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005, 20:559-569.
7. Shigeta M., Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001, 7:353-368.
8. Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002, 41:719-739.
9. Mihara M., Ohnishi A., Tomono Y., et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993, 31:223-229.
10. Barner E.L., Gray S.L. Donepezil use in Alzheimer disease. Ann Pharmacother 1998, 32:70-77.
11. Tiseo P.J., Perdomo C.A., Friedhoff L.T. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998, 46(Suppl 1):19-24.
12. Bhatt A.D., Vaidya A.B. Bio-availability and drug delivery systems: clinical perspective. J Postgrad Med 1992, 38:130-134.
13. US Food and Drug Administration. Guidance for Industry Orally Disintegrating Tablets. Washington, DC: US Department of Health and Human Services FaDAF, Center for Drug evaluation and Research (CDER).
14. Marrie T.J. Pneumonia in the long-term-care facility. Infect Control Hosp Epidemiol 2002, 23:159-164.
15. Ethical principles for medical research involving human subjects World Medical Association Declaration of Helsinki, Accessed February 12, 2011. http://www.wma.net/en/30publications/10policies/b3/index.html.
16. Korea good clinical practice (KGCP) guidelines [in Korean] Korea Food and Drug Administration, Accessed February 12, 2011. http://clinicaltrials.kfda.go.kr/guide/laws/board_list.jsp?category_seq=12.
17. Hao X.Y., Ding L., Li L.M., et al. Bioequivalence of donepezil capsule and tablet in humans. Yao Xue Xue Bao 2003, 38:392-394.
18. Rogers S.L., Friedhoff L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998, 46(Suppl 1):1-6.
19. Tiseo P.J., Rogers S.L., Friedhoff L.T. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998, 46(Suppl 1):13-18.
20. Chow S.C., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies 2000, 1-30. Marcel Dekker, New York, NY. 2nd ed.
21. Almeida S., Filipe A., Neves R., et al. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions. Arzneimittelforschung 2010, 60:116-123.
22. Chow S.C., Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn 2001, 28:155-169.
23. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-680.
24. Park J.Y., Kim K.A., Lee G.S., et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther 2004, 26:715-723.
25. Farolfi M., Powers J.D., Rescigno A. On the determination of bioequivalence. Pharmacol Res 1999, 39:1-4.
26. Chen L., Jiang X., Huang L., et al. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study. Clin Ther 2009, 31:2242-2248.
27. Erkent U., Koytchev R. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Arzneimittelforschung 2008, 58:255-258.
28. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003, 25:2875-2890.
29. Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005, 1:527-536.